公开(公告)号：US11845805B2

公开(公告)日：2023-12-19

申请号：US17558430

申请日：2021-12-21

Applicant: GENMAB A/S

Inventor： Brian Elliott ,  Tahamtan Ahmadi ,  Christopher W. L. Chiu ,  Esther C. W Breij ,  Ida Hiemstra ,  Maria N. Jure-Kunkel

IPC: A61P35/00 ,  A61K31/475 ,  A61K31/573 ,  A61K31/675 ,  A61K31/704 ,  C07K16/28 ,  A61K39/395 ,  A61K39/00

CPC classification number: C07K16/2887 ,  A61K31/475 ,  A61K31/573 ,  A61K31/675 ,  A61K31/704 ,  A61K39/3955 ,  A61P35/00 ,  C07K16/2809 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/565

Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).